Interferon Beta: From Molecular Level to Therapeutic Effects

International Review of Cell and Molecular Biology

Volumn 326, Issue , 2016, Pages 343-372

  Haji Abdolvahab, M ^a   Mofrad, M R K ^b   Schellekens, H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antibodies; epitopes; immunogenicity; interferon beta; molecular aggregates; multiple sclerosis

Indexed keywords

B LYMPHOCYTE ANTIGEN; BETA INTERFERON; BETA1A INTERFERON; EPITOPE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; PEGINTERFERON BETA1A; PROTEIN; PROTEIN AGGREGATE; RECOMBINANT BETA INTERFERON; T LYMPHOCYTE ANTIGEN; TERIFLUNOMIDE; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; B LYMPHOCYTE; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; EPITOPE MAPPING; FIBROBLAST; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MACROPHAGE; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; OSTEOBLAST; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION;

EID: 84979497434     PISSN: 19376448     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.ircmb.2016.06.001     Document Type: Chapter

References (186)

1. Aaronson, D.S., Horvath, C.M., A road map for those who don't know JAK-STAT. Science 296:5573 (2002), 1653–1655.
2. Arduini, R.M., Strauch, K.L., Runkel, L.A., Carlson, M.M., Hronowski, X., Foley, S.F., Young, C.N., Cheng, W., Hochman, P.S., Baker, D.P., Characterization of a soluble ternay complex formed between human interferon-β-1a and its receptor chains. Protein Sci. 8 (1999), 1867–1877.
3. Adams, G.P., Weiner, L.M., Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23:9 (2005), 1147–1157.
4. Agrawal, N.J., Kumar, S., Wang, X., Helk, B., Singh, S.K., Trout, B.L., Aggregation in protein-based biotherapeutics: Computational studies and tools to identify aggregation-prone regions. J. Pharm. Sci. 100:12 (2011), 5081–5095.
5. Antonelli, G., Reflections on the immunogenicity of therapeutic proteins. Clin. Microbiol. Infect. 14 (2008), 731–733.
6. Arduini, R.M., Li, Z., Rapoza, A., Gronke, R., Hess, D.M., Wen, D., Miatkowski, K., Coots, C., Kaffashan, A., Viseux, N., Delaney, J., Domon, B., Young, C.N., Boynton, R., Chen, L.L., Chen, L., Betzenhauser, M., Miller, S., Gill, A., Pepinsky, R.B., Hochman, P.S., Baker, D.P., Expression, purification, and characterization of rat interferon-β, and preparation of an N-terminally PEGylated form with improved pharmacokinetic properties. Protein Exp. Pur. 34 (2004), 229–242.
7. Baker, M.P., Carr, F.J., Carter, G., 2003, Method for mapping and eliminating T-cell epitopes. Patents, WO 2003104803 A2.
8. Baker, M.P., Reynolds, H.M., Lumicisi, B., Bryson, C.J., Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self/Nonself 1:4 (2010), 314–322.
9. Barak, Y., Achiron, A., Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur. Neurol. 47 (2002), 11–14.
10. Barnard, J.G., Babcock, K., Carpenter, J.F., Characterization and quantitation of aggregates and particles in interferon-b products: potential links between product quality attributes and immunogenicity. J. Pharm. Sci. 3:102 (2013), 915–927.
11. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E., The protein data bank. Nucleic Acids Res. 28:1 (2000), 235–242.
12. Bertolotto, A., Deisenhammer, F., Gallo, P., Sorensen, P.S., Immunogenicity of interferon beta: differences among products. J. Neurol. 251:2 (2004), 15–24.
13. Bhatti, Z., Berenson, C.S., Adult systemic cat scratch disease associated with therapy for hepatitis C. BMC Infect. Dis., 7, 2007, 8.
14. Boehr, D.D., Nussinov, R., Wright, P.E., The role of dynamic conformational ensembles in biomolecular recognition. Nat. Chem. Biol. 5:11 (2009), 789–796.
15. Borden, E.C., Sen, G.C., Uze, G., Silverman, R.H., Ransohoff, R.M., Foster, G.R., Stark, G.R., Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6 (2007), 975–990.
16. Bozhinov, A., Handzhiyski, Y., Genov, K., Daskalovska, V., Niwa, T., Ivanov, I., Mironova, R., Advanced glycation end products contribute to the immunogenicity of IFN-$ pharmaceuticals. J Allergy Clin. Immunol. 129:3 (2011), 855–858.
17. Busenlehner, L.S., Armstrong, R.N., Insights into enzyme structure and dynamics elucidated by amide H/D exchange mass spectrometry. Arch. Biochem. Biophys. 433 (2005), 34–46.
18. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., Denney, D.W. Jr., Leahy, D.J., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:6924 (2003), 756–760.
19. Cohen, B., Parkin, J., An overview of the immune system. Lancet 357:9270 (2001), 1777–1789.
20. Columbus, F.H., Treatment and Management of Multiple Sclerosis. 2004, Nova Biomedical Books, New York.
21. Comi, G., Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin. Ther. 31:6 (2009), 1142–1157.
22. Compston, A., Coles, A., Multiple sclerosis. Lancet 359:9313 (2002), 1221–1231.
23. Compston, A., Coles, A., Multiple sclerosis. Lancet 372:9648 (2008), 1502–1517.
24. Confavreux, C., Vukusic, S., Moreau, T., et al. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343:20 (2000), 1430–1438.
25. Conklin, D., Recognition of the Helical Cytokine Fold. J. Comp. Biol. 11:6 (2004), 1189–1200.
26. Creeke, P.I., Farrell, R.A., Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis. Ther. Adv. Neurol. Disord. 6:1 (2013), 3–17.
27. Crow, M.K., Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther., 12(Suppl 1), 2010, S5.
28. De Andrea, M., Gariglio, M., Gioia, D., Landolfo, S., Ravera, R., The interferon system: an overview. Eur. J. Paediatr. Neurol. 6:Suppl A (2002), A41–A46.
29. de Weerd, N.A., Samarajiwa, S.A., Hertzog, P.J., Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282:28 (2007), 20053–20057.
30. Deonarain, R., Alcam ́ı, A., Alexiou, M., Dallman, M.J., Gewert, D.R., Porter, A.C., Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J. Virol. 74 (2000), 3404–3409.
31. Dhib-Jalbut, S., Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 58 (2002), S3–S9.
32. Dhib-Jalbut, S., Marks, S., Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74:Suppl 1 (2010), S17–S24.
33. Domanski, P., Witte, M., Kellum, M., Rubinstein, M., Hackett, R., Pitha, P., et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 270 (1995), 21606–21611.
34. Escobar, G., Moi, D., Ranghetti, A., Ozkal-Baydin, P., Squadrito, M.L., Kajaste-Rudnitski, A., Bondanza, A., Gentner, B., De Palma, M., Mazzieri, R., Naldini, L., Genetic engineering of hematopoiesis for targeted IFN-α delivery inhibits breast cancer progression. Sci. Transl. Med. 6:217 (2014), 217–230.
35. Fazeli, A., Shojaosadati, S.A., Fazeli, M.R., Khalifeh, K., Ariaeenejad, S., Moosavi-Movahedi, A.A., The role of trehalose for metastable state and functional form of recombinant interferon beta-1b. J. Bioth. 163 (2013), 318–324.
36. Filippini, G., Munari, L., Incorvaia, B., Ebers, G.C., Polman, C., D'Amico, R., et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361 (2003), 545–552.
37. Foote, A.K., Blakemore, W.F., Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128:3 (2005), 528–539.
38. Fradkin, A.H., Carpenter, J.F., Randolph, T.W., Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J. Pharm. Sci. 98 (2009), 3247–3264.
39. Freedman, M.S., Hughes, B., Mikol, D.D., et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur. Neurol. 60:1 (2008), 1–11.
40. Freedman, M.S., Long-term follow-up of clinical trials of multiple sclerosis therapies. Neurology 76 (2011), 26–34.
41. Friedman, R.M., Contente, S., Treatment of hepatitis C infections with interferon: a historical perspective. Hepat. Res. Treat. 2010 (2010), 1–5.
42. Frokjaer, S., Otzen, D.E., Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov. 4 (2005), 298–306.
43. Giovannoni, G., Munschauer, F., Deisenhammer, F., Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 73:5 (2002), 465–469.
44. Giovannoni, G., Management of secondary-progressive multiple sclerosis. CNS Drugs 18:10 (2004), 653–669.
45. Goldsby, R.A., Kindt, T.J., Kuby, J., Osborne, B.A., Immunology. fifth ed., 2002, W. H. Freeman, New York.
46. Goodin, D.S., Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 9:71 (2008), 8–13.
47. Goodin, D.S., Frohman, E.M., Garmany, G.P., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58:2 (2002), 169–178.
48. Gneiss, C., Koudouovoh-Tripp, P.M., Ropele, S., Gotwald, T., Ehling, R., Lutterotti, A., Aichner, F., Ladurner, G., Eggers, C., Schautzer, F., Kunz, B., Millonig, A., Aspeck, E., Reindl, M., Berger, T., Fazekas, F., Deisenhammer, F., Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study. Mult. Scler. 15:12 (2009), 1481–1488.
49. Grandvaux, N., Servant, M.J., tenOever, B., Sen, G.C., Balachandran, S., Barber, G.N., Lin, R., Hiscott, J., Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76:11 (2002), 5532–5539.
50. Gray, D.S., Boll, W., Taira, H., Mantei, N., Len gyel, P., Weissmann, C., The biology of the interferon system. Nucl. Acid Res. 11 (1983), 555–573.
51. Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., et al. Type I interferon inhibits inter- leukin-1 production and inflammasome activation. Immunity 34 (2011), 213–223.
52. Guo, B., Chang, E.Y., Cheng, G., The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J. Clin. Invest. 118 (2008), 1680–1690.
53. Hamming, O.J., Lutfalla, G., Levraud, J.P., Hartmann, R., Crystal structure of Zebrafish interferons I and II reveals conservation of type I interferon structure in vertebrates. J. Virol. 85:16 (2011), 8181–8187.
54. Hartung, H.P., Munschauer, F. 3rd, Schellekens, H., Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur. J. Neurol. 12:8 (2005), 588–601.
55. Hassan-Smith, G., Douglas, M.R., Management and prognosis of multiple sclerosis. Br. J. Hosp. Med. 72:11 (2011), 174–176.
56. He, D., Xu, Z., Dong, S., Zhang, H., Zhou, H., Wang, L., Zhang, S., 2012. Teriflunomide for multiple sclerosis. Cochrane Database Syst. Rev.;12:CD009882.
57. Hebenstreit, D., Horejs-Hoeck, J., Duschl, A., JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 18:4 (2005), 243–249.
58. Hermant, P., Michiels, T., Interferon-λ in the context of viral infections: production, response and therapeutic implications. J. Innate Immun. 6:5 (2014), 563–574.
59. Hermeling, S., Crommelin, D.J.A., Schellekens, H., Jiskoot, W., Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:6 (2004), 897–903.
60. Hermeling, S., Aranha, L., Damen, J.M.A., Slijper, M., Schellekens, H., Crommelin, D.J.A., et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm. Res. 22 (2005), 1997–2006.
61. Hermeling, S., Jiskoot, W., Crommelin, D.J.A., Bornæs, C., Schellekens, H., Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. 22:6 (2005), 847–851.
62. Hermeling, S., Schellekens, H., Maas, C., Gebbink, M.F., Crommelin, D.J., Jiskoot, W., Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci. 95:5 (2006), 1084–1096.
63. Hinterdorfer, P., Dufrêne, Y.F., Detection and localization of single molecular recognition events using atomic force microscopy. Nat. Methods. 3:5 (2006), 347–355.
64. Hinton, H.J., et al. Pattern recognition by B cells: the role of antigen repetitiveness versus Toll-like receptors. Curr. Top. Microbiol. Immunol. 319 (2008), 1–15.
65. Horvath, C.M., STAT proteins and transcriptional responses to ex- tracellular signals. Trends Biochem. Sci. 25 (2000), 496–502.
66. Huang, J., Honda, W., CED: a conformational epitope database. BMC Immunol., 7, 2006, 7.
67. Huang, H., Ito, K., Dangond, F., et al. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. J. Neuroimmunol. 258 (2013), 27–31.
68. Ivanova, M.I., Thompson, M.J., Eisenberg, D., A systematic screen of beta(2)-microglobulin and insulin for amyloid-like segments. Proc. Natl. Acad. Sci. USA 103:11 (2006), 4079–4082.
69. Ivanova, M.I., Sievers, S.A., Sawaya, M.R., Wall, J.S., Eisenberg, D., Molecular basis for insulin fibril assembly. Proc. Natl. Acad. Sci. USA 106:45 (2009), 18990–18995.
70. Javed, A., Reder, A.T., Therapeutic role of beta-interferons in multiple sclerosis. Pharmacol. Ther. 110:1 (2006), 35–56.
71. Jiang, L., et al. De novo computational design of retro-aldol enzymes. Science 319 (2008), 1387–1391.
72. Jaitin, D.A., Roisman, L.C., Jaks, E., Gavutis, M., Piehler, J., Van der Heyden, J., Uze, G., Schreiber, G., Inquiring into the Differential Action of Interferons (IFNs): an IFN-α2 Mutant with Enhanced Affinity to IFNAR1 Is Functionally Similar to IFN-β. Mol. Cell. Biol. 26:5 (2006), 1888–1897.
73. Kaltashov, I.A., Bobst, C.E., Abzalimov, R.R., Berkowitz, S.A., Houde, D., Conformation and dynamics of biopharmaceuticals: transition of mass spectrometry-based tools from academe to industry. J. Am. Soc. Mass Spectrom. 21:3 (2010), 323–337.
74. Karpusas, M., Nolte, M., Benton, C.B., Meier, W., Lipscomb, W.N., Goelz, S., The crystal structure of human interferon beta at 2.2-A° resolution. Proc. Natl. Acad. Sci. USA 94 (1997), 11813–11818.
75. Karpusas, M., Whitty, A., Runkel, L., Hochman, P., The structure of human interferon-β: implications for activity. Cell. Mol. Life. Sci. 54 (1998), 1203–1216.
76. Kasper, L.H., Shoemaker, J., Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 74:1 (2010), S2–S8.
77. Katze, M.G., He, Y., et al. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol. 2:9 (2002), 675–687.
78. Kaur, S., Sassano, A., Dolniak, B., Joshi, S., Majchrzak-Kita, B., Baker, D.P., Hay, N., Fish, E.N., Platanias, L.C., Role of the Akt Pathway in mRNA Translation of Interferon-Stimulated Genes. Proc. Natl. Acad. Sci. USA 105 (2008), 4808–4813.
79. Kawaguchi, Y., Miyamoto, Y., Inoue, T., Kaneda, Y., Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 124:10 (2009), 2478–2487.
80. Kijanka, G., Jiskoot, W., Schellekens, H., Brinks, V., Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice. Pharm. Res. 30:6 (2013), 1553–1560.
81. Kim, R., Emi, M., Tanabe, K., Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1 (2007), 1–14.
82. Knobler, R.L., Greenstein, J.I., Johnson, K.P., Lublin, F.D., Panitch, H.S., Conway, K., Grant-Gorsen, S.V., Muldoon, J., Marcus, S.G., Wallenberg, J.C., Williams, G.J., Yoshizawa, C.N., Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon Res. 13 (1993), 333–340.
83. Kohlhapp, F.J., Kaufman, H.L., Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin. Cancer Res. Clincanres 22:5 (2015), 2667–2674.
84. Krebs, D.L., Hilton, D.J., SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19:5 (2001), 378–387.
85. Krumbholz, M., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (2008), 1455–1463.
86. Kuo, P., Scofield, B.A., Yu, I., Chang, F., Ganea, D., Yen, J., Interferon-b modulates inflammatory response in cerebral ischemia. J. Am. Heart. Assoc., 5, 2016, e002610.
87. Kumar, S., Mitnik, C., Valente, G., Floyd-Smith, G., Expansion and molecular evolution of the interferon-induced 2’-5’ oligoadenylate synthetase gene family. Mol. Biol. Evol. 17:5 (2000), 738–750.
88. Kumar, S., Ma, B., Tsai, C.J., Sinha, N., Nussinov, R., Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci. 9 (2000), 10–19.
89. Kumar, S., Wang, X., Singh, S.K., Identification and impact of aggregation-prone regions in proteins and therapeutic monoclonal antibodies. Wang, W., Roberts, C.J., (eds.) Aggregation of therapeutic proteins., 2010, John Wiley & Sons, Inc, Hoboken, New Jersey, 103–118.
90. Kumar, S., Singh, S.K., Wang, X., Rup, B., Gill, D., Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions. Pharm. Res. 28 (2011), 949–961.
91. Kumar, S., Mitchell, M.A., Rup, B., Singh, S.K., Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: Implications for rational design of novel and follow-on therapeutic antibodies. J. Pharm. Sci. 101:8 (2012), 2686–2701.
92. Kumaran, J., Wei, L., Kotra, L.P., Fish, E.N., A structural basis for interferon-receptor interactions. FASEB J. 21 (2007), 3288–3296.
93. Lau, J.F., Parisien, J.P., Horvath, C.M., Interferon regulatory factor subcellular localization is determined by a bipartite nuclear localization signal in the DNA-binding domain and interaction with cytoplasmic retention factors. Proc. Natl. Acad. Sci. USA 97 (2000), 7278–7283.
94. Laurence, J.S., Middaugh, R.C., Fundamental structures and behaviors of proteins. Wang, W., Roberts, C.J., (eds.) Aggregation of therapeutic proteins, 2010, Wiley, Hoboken, 1–61.
95. Leary, S.M., Thompson, A.J., Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 19:5 (2005), 369–376.
96. Le Bon, A., Tough, D.F., Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14 (2002), 432–436.
97. Li, S., Schmitz, K.R., Jeffrey, P.D., Wiltzius, J.J., Kussie, P., Ferguson, K.M., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:4 (2005), 301–311.
98. Liu, Y.J., IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol. 23 (2005), 275–306.
99. Loignon, M., Perret, S., Kelly, J., Boulais, D., Cass, B., Bisson, L., Afkhamizarreh, F., Durocher, Y., Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol. 8 (2008), 65–81.
100. Mackay, F., Schneider, P., Cracking the BAFF code. Nat. Rev. Immunol. 9 (2009), 491–502.
101. McKay, F.C., Hoe, E., Parnell, G., Gatt, P., Schibeci, S.D., Stewart, G.J., Booth, D.R., IL7Rα expression and upregulation by IFNβ in dendritic cell subsets is haplotype-dependent. PLoS One, 8(10), 2013, e77508.
102. Manouchehrinia, A., Constantinescu, C.S., Cost-effectiveness of disease-modifying therapies in multiple sclerosis. Current Neurol. Neurosci. Rep. 12:5 (2012), 592–600.
103. Matsuo, H., Kohno, K., Niihara, H., Morita, E., Specific IgE determination to epitope peptides of {omega}-5 gliadin and high molecular weight glutenin subunit is a useful tool for diagnosis of wheat-dependent exercise-induced anaphylaxis. J. Immunol. 175:12 (2005), 8116–8122.
104. McCarthy, S.D.S., Majchrzak-Kita, B., Racine, T., Kozlowski, H.N., Baker, D.P., Hoenen, T., Kobinger, G.P., Fish, E.N., Branch, D.R., A rapid screening assay identifies monotherapy with interferon-β and combination therapies with nucleoside analogs as effective inhibitors of ebola virus. PLOS Negl. Trop. Dis., 10, 2016, e0004364.
105. McCormack, P.L., Scott, L.J., Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 18:8 (2004), 521–546.
106. McCormack, P.L., Scott, L.J., Spotlight on interferon-β-1b in relapsing-remitting and secondary progressive multiple sclerosis. Biodrugs 18:5 (2004), 343–347.
107. McKeage, K., Interferon-beta-1b: in newly emerging multiple sclerosis. CNS Drugs 22:9 (2008), 787–792.
108. Mehrotra, S., Sharma, B., Joshi, S., Kroczynska, B., Majchrzak, B., Stein, B.L., McMahon, B., Altman, J.K., Licht, J.D., Baker, D.P., Eklund, E.A., Wickrema, A., Verma, A., Fish, E.N., Platanias, L.C., Essential role for Mnk-pathway in the inhibitory effects of type i interferons on myeloproliferative neoplasm (MPN) precursors. J. Biol. Chem. 288 (2013), 23814–23822.
109. Meinl, E., Krumbholz, M., Hohlfeld, R., B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59 (2006), 880–892.
110. Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54:6 (1988), 903–913.
111. Morris, G.E., 2007, Epitope Mapping: B-cell Epitopes. Encyclopedia of Life Sciences, Wiley, pp. 1–3. a0002624.pub2. http://www.els.net.
112. Moss, C.X., Matthews, S.P., Lamont, D.J., Watts, C., Asparagine deamidation perturbs antigen presentation on class II major histocompatibility complex molecules. J. Biol. Chem. 280:18 (2005), 18498–18503.
113. Munari, L., Lovati, R., Boiko, A., 2004. Therapy with glatiramer acetate for multiple sclerosis. Cochrane database of systematic reviews (Online).
114. Murray, E.D., Buttner, E.A., Price, B.H., Depression and psychosis in neurological practice. Daroff, R., Fenichel, G., Jankovic, J., Mazziotta, J., (eds.) Bradley's Neurology in Clinical Practice, sixth ed., 2012, Elsevier/Saunders, Philadelphia, PA.
115. Nakahara, J., Maeda, M., Aiso, S., Suzuki, N., Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin. Rev. Allergy Immunol. 42:1 (2012), 26–34.
116. Nelson, R., Sawaya, M.R., Balbirnie, M., Madsen, A.O., Riekel, C., Grothe, R., Eisenberg, D., Structure of the cross-beta spine of amyloid-like fibrils. Nature 435:7043 (2005), 773–778.
117. Nguyen, H., Hiscott, J., Pitha, P.M., The growing family of interferon regulatory factors. Cytokine Growth Factor Rev. 8 (1997), 293–312.
118. Nielsen, M., Lund, O., Buus, S., Lundegaard, C., MHC Class II epitope predictive algorithms. Immunology 130:3 (2010), 319–328.
119. Nybakken, G.E., Oliphant, T., Johnson, S., Burke, S., Diamond, M.S., Fremont, D.H., Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:7059 (2005), 764–769.
120. Palmer, A.G., Nmr probes of molecular dynamics: overview and comparison with other techniques. Annu. Rev. Biophys. Biomol. Struct. 30 (2001), 129–155.
121. Paolicelli, D., Direnzo, V., Trojano, M., Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics 3 (2009), 369–376.
122. Piehler, J., Thomas, C., Garcia, K.C., Schreiber, G., Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250:1 (2012), 317–334.
123. Plosker, G.L., Interferon-β-1b. CNS Drugs 25:1 (2011), 67–88.
124. Ponomarenko, J.V., van Regenmortel, M.H.V., 2009. B-cell epitope prediction. Structural Bioinformatics, Second Edition, John Wiley & Sons, Inc. 35, 849–880.
125. Porter, S., Human immune response to recombinant human proteins. J. Pharm. Sci. 90 (2001), 1–11.
126. Pugliatti, M., Rosati, G., Carton, H., et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13 (2006), 700–722.
127. Qizilbash, N., Mendez, I., Sanchez-de la Rosa, R., Benefit-risk analysis of glatiramer acetate for relapsing-remitting and clinically isolated syndrome multiple sclerosis. Clin. Ther. 34:1 (2012), 159–176.e5.
128. Reang, P., Gupta, M., Kohli, K., Biological response modifiers in cancer. Med. Gen. Med., 8(4), 2006, 33.
129. Rauch, I., Muller, M., Decker, T., The regulation of inflammation by interferons and their STATs. JAKSTAT, 2, 2013, e23820.
130. Reder, A.T., Feng, X., How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J. Interferon Cytokine Res. 34 (2014), 589–599.
131. Reingold, S.C., Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:4 (1996), 907–911.
132. Reveille, J.D., The genetic basis of autoantibody production. Autoimmun. Rev. 5 (2006), 389–398.
133. Riemer, A.B., Kurz, H., Klinger, M., Scheiner, O., Zielinski, C.C., JensenJarolim, E., Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J. Natl. Cancer Inst. 97:22 (2005), 1663–1670.
134. Rifkin, R.A., Maggio, E.T., Dike, S., Kerr, D.A., Levy, M., n-Dodecyl-beta-D-maltoside inhibits aggregation of human interferon-beta-1b and reduces its immunogenicity. J. Neuroimmune Pharmacol. 6:1 (2011), 158–162.
135. Rojas, J.I., Romano, M., Ciapponi, A., Patrucco, L., Cristiano, E., 2010. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev;(1):CD006643.
136. Rosenberg, A.S., Effects of protein aggregates: an immunologic perspective. AAPS J. 8:3 (2006), 501–507.
137. Rothlisberger, D., et al. Kemp elimination catalysts by computational enzyme design. Nature 453 (2008), 190–195.
138. Runkel, L., Meier, W., Pepinsky, R.B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., Goelz, S.E., Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15 (1998), 641–649.
139. Samuel, C.E., Antiviral actions of interferons. Clin. Microbiol. Rev. 14:4 (2001), 778–809.
140. Sandrock, A., 2005. Therapies for chronic inflammatory demyelinating polyneuropathy using interferon. Patent EP20030798770.
141. Sanford, M., Lyseng-Williamson, K.A., Subcutaneous recombinantinterferon-b-1a (Rebif): a review of its use in the treatment of relapsing multiple sclerosis. Drugs 71:14 (2011), 1865–1891.
142. Sauerborn, M., Brinks, V., Jiskoot, W., Schellekens, H., Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 31:2 (2010), 53–59.
143. Sawaya, M.R., Sambashivan, S., Nelson, R., Ivanova, M.I., Sievers, S.A., Apostol, M.I., Thompson, M.J., Balbirnie, M., Wiltzius, J.J., McFarlane, H.T., Madsen, A.O., Riekel, C., Eisenberg, D., Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447:7143 (2007), 453–457.
144. Saxena, A.K., Singh, K., Su, H.P., Klein, M.M., Stowers, A.W., Saul, A.J., Long, C.A., Garboczi, D.N., The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat. Struct. Mol. Biol. 13:1 (2005), 90–91.
145. Schellekens, H., Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1 (2002), 457–462.
146. Schellekens, H., Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24 (2002), 1720–1740.
147. Schellekens, H., How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol. Annu. Rev. 14 (2008), 191–202.
148. Sedmak, J.J., Jameson, P., Grossberg, S.E., Human Interferon: Production and Clinical Use. 1978, Plenum Press, New York 133–152.
149. Seger, R.A., Modern management of chronic granulomatous disease. Br. J. Haematol. 140 (2008), 255–266.
150. Shapiro, A.M., Jack, C.S., Lapierre, Y., Arbour, N., Bar-Or, A., Antel, J.P., Potential for interferon beta-induced serum antibodies in multiple sclerosis to inhibit endogenous interferon regulated chemokine/cytokine responses within the central nervous system. Arch. Neurol. 63:9 (2006), 1296–1299.
151. Shirley, B.A., Babuka, S., Chen, B.L., Hora, M., Choe, M., Teller, M., 2008. HSA-free formulations of interferon-beta, P. No.US 7,399,463 B2.
152. Simora, R.M.C., Ohtani, M., Hikima, J., Kondo, H., Hirono, E., Sung Jung, T., Aoki, T., Molecular cloning and antiviral activity of IFN-β promoter stimulator-1 (IPS-1) gene in Japanese flounder, Paralichthys olivaceus. Fish Shellfish Immunol. 29 (2010), 979–986.
153. Singh, S.K., Impact of product-related factors on immunogenicity of biotherapeutics. J. Pharm. Sci. 100:2 (2011), 354–387.
154. Smith, L.M., Hensley, L.E., Geisbert, T.W., Johnson, J., Stossel, A., Honko, A., et al. Interferon-beta therapy prolongs survival in rhesus macaque models of Ebola and Marburg hemorrhagic fever. J. Infect. Dis. 208 (2013), 310–318.
155. Sola’, R.J., Griebenow, K., Effects of glycosylation on the stability of protein pharmaceuticals. J. Pharm. Sci. 98:4 (2009), 1223–1245.
156. Song, K., Yoon, I., Kim, N.A., Kim, D., Lee, J., Lee, H.J., Lee, S., Choi, S., Choi, M., Kim, H.H., Jeong, S.H., Son, W.S., Kim, D., Shin, Y.K., the higher specific activities of IFNβ-1a are likely caused by glycosylation-induced stabilization, and the higher α-helical content. PLoS One, 9(5), 2014, e96967.
157. Sorensen, P.S., Review: neutralizing antibodies against interferon beta. Ther. Adv. Neurol. Disord. 1 (2008), 125–141.
158. Sorensen, P.S., Koch-Henriksen, N., Flachs, E.M., Bendtzen, K., Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?. Mult. Scler. 14 (2008), 837–842.
159. SPECTRIMS study group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 56 (2001), 1496–1504.
160. Strauss, E.G., Strauss, J.H., 2007. Viruses and Human Disease. Elsevier, Amsterdam, 1–467.
161. Stuve, O., Bennett, J.L., Hemmer, B., et al. Pharmacological treatment of early multiple sclerosis. Drugs 68:1 (2008), 73–83.
162. Talon, J., Horvath, C.M., Polley, R., Basler, C.F., Muster, T., Palese, P., García-Sastre, A., Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74:17 (2000), 7989–7996.
163. Tan, N.Y., Bailey, U., Jamaluddin, M.F., Mahmud, S.H.B., Raman, S.C., Schulz, B.L., Sequence-based protein stabilization in the absence of glycosylation. Nat. Commun. 5 (2014), 3099–3106.
164. Thompson, A.J., Montalban, X., Barkhof, F., et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann. Neurol. 47:6 (2000), 831–835.
165. Tremlett, H., Oger, J., Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J. Neurol. 251:11 (2004), 1297–1303.
166. Trisolini, M., Honeycutt, M.A. Wiener, J., Lesesne, S., 2010. Global Economic Impact of Multiple Sclerosis. RTI Project Number 0211748.000.001.
167. Tsang, B.K., Macdonell, R., Multiple sclerosis—diagnosis, management and prognosis. Aust. Fam. Physician 40:12 (2011), 948–955.
168. Uzé, G., Schreiber, G., Piehler, J., Pellegrini, S., The receptor of the type I interferon family. Curr. Top. Microbiol. Immunol. 316 (2007), 71–95.
169. Vallittu, A.M., Saraste, M., Airas, L., CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol. Res. 29 (2007), 763–766.
170. van Beers, M.M.C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., Jiskoot, W., Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm. Res. 27 (2010), 1812–1824.
171. van Beers, M.M.C., Sauerborn, M., Gilli, F., Brinks, V., Schellekens, H., Jiskoot, W., Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm. Res. 28 (2011), 2393–2402.
172. Varedi, M., The JAK-STAT signaling pathway of interferons system: snapshots. Iran. J. Immunol. 2:2 (2005), 67–77.
173. Vervoordeldonk, M.J., Aalbers, C.J., Tak, P.P., Interferon β for rheumatoid arthiritis: new clothes fora n old kid on the block. Ann. Rheum. Dis. 68 (2009), 157–158.
174. Vilcek, J., Novel interferons. Nat. Immunol. 4 (2003), 8–9.
175. Vilcek, J., Fifty years of interferon research: aiming at a moving target. Immunity 25 (2006), 343–348.
176. Vinion-Dubiel, A.D., McClain, M.S., Cao, P., Mernaugh, R.L., Cover, T.L., Antigenic diversity among Helicobacter pylori vacuolating toxins. Infect. Immun. 69:7 (2001), 4329–4336.
177. Vos, Q., et al. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev. 176 (2000), 154–170.
178. Vosoughi, R., Freedman, M.S., Therapy of MS. Clin. Neurol. Neurosurg. 112 (2010), 365–385.
179. Weber, C.A., Mehta, P.J., Ardito, M., Moise, L., Martin, B., De Groot, A.S., T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv. Drug Deliv. Rev. 61:11 (2009), 965–976.
180. Wee Yong, V., Differential mechanisms of action of interferon-β and glatiramer acetate in MS. Neurology 59 (2002), 1–7.
181. Weiner, H.L., The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. Ann. Neurol. 65 (2009), 239–248.
182. Wolbink, G.J., Aarden, L.A., Dijkmans, B.A., Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr. Opin. Rheumatol. 21 (2009), 211–215.
183. World Health Organization, 2008. Multiple Sclerosis International Federation. Atlas: multiple sclerosis resources in the world. Available from: http://www.msif.org/en/about_msif/what_we_do/atlas_of_ms/.
184. Yang, X., Zhang, X., Fu, M.L., Weichselbaum, R.R., Gajewski, T.F., Guo, Y., Fu, Y.X., Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25:1 (2014), 37–48.
185. Yeung, P., Chang, J., Miller, J., Barnett, C., Stickler, M., Harding, F., Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172 (2004), 6658–6665.
186. Züst, R., Toh, Y.X., Valdés, I., Cerny, D., Heinrich, J., Hermida, L., Marcos, E., Guillén, G., Kalinke, U., Shi, P.Y., Fink, K., Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J. Virol. 88:13 (2014), 7276–7285.